CLRB - Cellectar Biosciences announces up to ~$103M private placement financing
2023-09-05 12:14:58 ET
- Cellectar Biosciences ( NASDAQ: CLRB ), a late-stage clinical biopharmaceutical company, Tuesday said it has entered into a securities purchase agreement with certain institutional investors for a private placement financing that is expected to result in gross proceeds of up to $102.9 million.
- The PIPE financing includes an initial funding of $24.5 million priced at $1.82 per share.
-
The transaction is led by existing investor Rosalind with participation from other new and existing healthcare-focused institutional investors.
-
Pivotal topline data in Waldenstrom’s macroglobulinemia expected in Q4 2023 with NDA submission and potential product launch in 2024, the company said.
- CLRB is +28.02% to $2.33
- Source: Press Release
For further details see:
Cellectar Biosciences announces up to ~$103M private placement financing